126 related articles for article (PubMed ID: 20142255)
1. Human papillomavirus types 16, 18, and 31 serostatus and prostate cancer risk in the Prostate Cancer Prevention Trial.
Sutcliffe S; Viscidi RP; Till C; Goodman PJ; Hoque AM; Hsing AW; Thompson IM; Zenilman JM; De Marzo AM; Platz EA
Cancer Epidemiol Biomarkers Prev; 2010 Feb; 19(2):614-8. PubMed ID: 20142255
[TBL] [Abstract][Full Text] [Related]
2. Plasma antibodies against Chlamydia trachomatis, human papillomavirus, and human herpesvirus type 8 in relation to prostate cancer: a prospective study.
Sutcliffe S; Giovannucci E; Gaydos CA; Viscidi RP; Jenkins FJ; Zenilman JM; Jacobson LP; De Marzo AM; Willett WC; Platz EA
Cancer Epidemiol Biomarkers Prev; 2007 Aug; 16(8):1573-80. PubMed ID: 17684131
[TBL] [Abstract][Full Text] [Related]
3. Human papillomavirus 16, 18, and 33 infections and risk of prostate cancer: a Nordic nested case-control study.
Korodi Z; Dillner J; Jellum E; Lumme S; Hallmans G; Thoresen S; Hakulinen T; Stattin P; Luostarinen T; Lehtinen M; Hakama M
Cancer Epidemiol Biomarkers Prev; 2005 Dec; 14(12):2952-5. PubMed ID: 16365015
[TBL] [Abstract][Full Text] [Related]
4. Prospective study of human herpesvirus type 8 serostatus and prostate cancer risk in the placebo arm of the Prostate Cancer Prevention Trial.
Sutcliffe S; Till C; Jenkins FJ; Gaydos CA; Goodman PJ; Hoque AM; Hsing AW; Thompson IM; Nelson WG; De Marzo AM; Platz EA
Cancer Causes Control; 2015 Jan; 26(1):35-44. PubMed ID: 25359302
[TBL] [Abstract][Full Text] [Related]
5. Prostate cancer risk and serologic evidence of human papilloma virus infection: a population-based case-control study.
Adami HO; Kuper H; Andersson SO; Bergström R; Dillner J
Cancer Epidemiol Biomarkers Prev; 2003 Sep; 12(9):872-5. PubMed ID: 14504197
[TBL] [Abstract][Full Text] [Related]
6. HPV persistence and its oncogenic role in prostate tumors.
Tachezy R; Hrbacek J; Heracek J; Salakova M; Smahelova J; Ludvikova V; Svec A; Urban M; Hamsikova E
J Med Virol; 2012 Oct; 84(10):1636-45. PubMed ID: 22930513
[TBL] [Abstract][Full Text] [Related]
7. Prospective study of cytomegalovirus serostatus and prostate cancer risk in the Prostate Cancer Prevention Trial.
Sutcliffe S; Till C; Gaydos CA; Jenkins FJ; Goodman PJ; Hoque AM; Hsing AW; Thompson IM; Zenilman JM; Nelson WG; De Marzo AM; Platz EA
Cancer Causes Control; 2012 Sep; 23(9):1511-8. PubMed ID: 22810146
[TBL] [Abstract][Full Text] [Related]
8. Implication of high risk human papillomavirus HR-HPV infection in prostate cancer in Indian population--a pioneering case-control analysis.
Singh N; Hussain S; Kakkar N; Singh SK; Sobti RC; Bharadwaj M
Sci Rep; 2015 Jan; 5():7822. PubMed ID: 25592643
[TBL] [Abstract][Full Text] [Related]
9. Worldwide Prevalence of Human Papillomavirus and Relative Risk of Prostate Cancer: A Meta-analysis.
Yang L; Xie S; Feng X; Chen Y; Zheng T; Dai M; Zhou CK; Hu Z; Li N; Hang D
Sci Rep; 2015 Oct; 5():14667. PubMed ID: 26441160
[TBL] [Abstract][Full Text] [Related]
10. Human papillomavirus 16 or 18 infection and prostate cancer risk: a meta-analysis.
Lin Y; Mao Q; Zheng X; Yang K; Chen H; Zhou C; Xie L
Ir J Med Sci; 2011 Jun; 180(2):497-503. PubMed ID: 21400096
[TBL] [Abstract][Full Text] [Related]
11. Case-control study of human papillomavirus and oropharyngeal cancer.
D'Souza G; Kreimer AR; Viscidi R; Pawlita M; Fakhry C; Koch WM; Westra WH; Gillison ML
N Engl J Med; 2007 May; 356(19):1944-56. PubMed ID: 17494927
[TBL] [Abstract][Full Text] [Related]
12. Human papillomavirus and oral cancer: the International Agency for Research on Cancer multicenter study.
Herrero R; Castellsagué X; Pawlita M; Lissowska J; Kee F; Balaram P; Rajkumar T; Sridhar H; Rose B; Pintos J; Fernández L; Idris A; Sánchez MJ; Nieto A; Talamini R; Tavani A; Bosch FX; Reidel U; Snijders PJ; Meijer CJ; Viscidi R; Muñoz N; Franceschi S;
J Natl Cancer Inst; 2003 Dec; 95(23):1772-83. PubMed ID: 14652239
[TBL] [Abstract][Full Text] [Related]
13. Seroprevalence of human papillomaviruses and Chlamydia trachomatis and cervical cancer risk: nested case-control study.
Naucler P; Chen HC; Persson K; You SL; Hsieh CY; Sun CA; Dillner J; Chen CJ
J Gen Virol; 2007 Mar; 88(Pt 3):814-822. PubMed ID: 17325353
[TBL] [Abstract][Full Text] [Related]
14. Association between human papillomavirus infection and prostate cancer: A global systematic review and meta-analysis.
Moghoofei M; Keshavarz M; Ghorbani S; Babaei F; Nahand JS; Tavakoli A; Mortazavi HS; Marjani A; Mostafaei S; Monavari SH
Asia Pac J Clin Oncol; 2019 Oct; 15(5):e59-e67. PubMed ID: 30740893
[TBL] [Abstract][Full Text] [Related]
15. Cervical human papillomavirus (HPV) infection and HPV type 16 antibodies in South African women.
Marais DJ; Constant D; Allan B; Carrara H; Hoffman M; Shapiro S; Morroni C; Williamson AL
J Clin Microbiol; 2008 Feb; 46(2):732-9. PubMed ID: 18077644
[TBL] [Abstract][Full Text] [Related]
16. Trichomonosis and subsequent risk of prostate cancer in the Prostate Cancer Prevention Trial.
Sutcliffe S; Alderete JF; Till C; Goodman PJ; Hsing AW; Zenilman JM; De Marzo AM; Platz EA
Int J Cancer; 2009 May; 124(9):2082-7. PubMed ID: 19117055
[TBL] [Abstract][Full Text] [Related]
17. Human papillomavirus and risk of prostate cancer: a systematic review and meta-analysis.
Russo GI; Calogero AE; Condorelli RA; Scalia G; Morgia G; La Vignera S
Aging Male; 2020 Jun; 23(2):132-138. PubMed ID: 29571270
[No Abstract] [Full Text] [Related]
18. Human papillomavirus 16 and 18 L1 serology compared across anogenital cancer sites.
Carter JJ; Madeleine MM; Shera K; Schwartz SM; Cushing-Haugen KL; Wipf GC; Porter P; Daling JR; McDougall JK; Galloway DA
Cancer Res; 2001 Mar; 61(5):1934-40. PubMed ID: 11280749
[TBL] [Abstract][Full Text] [Related]
19. Impact of Serum Antibodies to HPV Serotypes 6, 11, 16, and 18 to Risks of Subsequent Genital HPV Infections in Men: The HIM Study.
Pamnani SJ; Sudenga SL; Viscidi R; Rollison DE; Torres BN; Ingles DJ; Abrahamsen M; Villa LL; Lazcano-Ponce E; Salmeron J; Quiterio M; Huang Y; Borenstein A; Giuliano AR
Cancer Res; 2016 Oct; 76(20):6066-6075. PubMed ID: 27535333
[TBL] [Abstract][Full Text] [Related]
20. Seroprevalence of HPV vaccine types 6, 11, 16 and 18 in HIV-infected women from South Africa, Brazil and Botswana.
Firnhaber C; Evans D; Friedman-Khalili R; Willliams S; Michelow P; Matlhagela K; Wester C; Grinsztejn B; Lockman S
J Clin Virol; 2011 Nov; 52(3):265-8. PubMed ID: 21908233
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
